Thromb Haemost 1981; 46(03): 648-651
DOI: 10.1055/s-0038-1653439
Original Article
Schattauer GmbH Stuttgart

Enhanced Antithrombotic Mechanisms in Patients with Maturity-Onset Diabetes mellitus without Thromboembolic Complications

G Grignani
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
G Gamba
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
D Geroldi
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
L Pacchiarini
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
B Solerte
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
E Ferrari
The Department of Clinical Medicine I° “Adolfo Ferrata” of the University of Pavia, Italy
,
E Ascario
°   The Department of Medical Pathology of the University of Pavia, Italy
› Author Affiliations
Further Information

Publication History

Received 04 May 1981

Accepted 26 August 1981

Publication Date:
05 July 2018 (online)

Preview

Summary

Some haemostatic parameters have been evaluated in a group of rigorously selected patients with maturity-onset diabetes mellitus without thromboembolic complications and in apparently normal subjects of the same age before and after the venous occlusion test (VOT).

In basal conditions diabetics had higher levels of AT III as biological activity and higher fibrinolytic and antifibrinolytic activities than controls

After VOT, F VIII R:Ag increased significantly in both groups, more markedly in controls than in diabetics, while F VIII: C showed no modification.

Also AT III R:Ag increased after the test, but such variation was significant only in diabetics; on the contrary, the biological activity of AT III was always significantly decreased after the test.

After VOT there were also in both groups highly significant increases in the fibrinolytic and antifibrinolytic activities.

Finally, HbA1c levels directly correlated with AT III as biological activity before VOT, but with no other parameter either before or after the test.

These data suggest the existence in patients with diabetes mellitus without thromboembolic complications of an activated protective mechanism against intravascular clotting.